ENA-001 is under clinical development by Enalare Therapeutics and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ENA-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ENA-001 overview
ENA-001 is under development for the treatment or prevention of drug-over dose respiratory depression, post operative respiratory depression, infection related respiratory distress (COVID-19), apnea of prematurity and infection related hypoxemia. The drug candidate is administered through intravenous, intravenous bolus intramuscular and oral route. It is a new chemical entity and acts by targeting calcium activated potassium channel subunit alpha 1 (KCNMA1). It was under development for the treatment or prevention of central/mixed sleep apnea.
Enalare Therapeutics overview
Enalare Therapeutics operates in the pharmaceuticals and healthcare sector, specializing in treating respiratory depression (hypoventilation). The company is headquartered in Princeton, New Jersey, the US.
For a complete picture of ENA-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
